- Home
- PANW vs GILD Comparison
PANW vs GILD Comparison
Compare PANW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | GILD |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4B | 187.4B |
| IPO Year | 2012 | 2003 |
Fundamental Metrics
Financial Performance| Metric | PANW | GILD |
|---|---|---|
| Price | $401.94 | $150.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 55 | 28 |
| Target Price | ★ $396.92 | $159.38 |
| AVG Volume (30 Days) | ★ 5.4M | 5.1M |
| Earning Date | 11-18-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.17% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ 0.40 | N/A |
| Revenue | $2,273,100,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $23.46 | $4.35 |
| Revenue Next Year | $14.49 | $6.57 |
| P/E Ratio | $1,045.60 | ★ N/A |
| Revenue Growth | ★ 29.04 | 9.98 |
| 52 Week Low | $139.57 | $114.02 |
| 52 Week High | $432.33 | $157.29 |
Technical Indicators
Market Signals| Indicator | PANW | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 55.82 |
| Support Level | $314.96 | $142.99 |
| Resistance Level | N/A | $152.04 |
| Average True Range (ATR) | 14.93 | 3.12 |
| MACD | 0.85 | -0.26 |
| Stochastic Oscillator | 52.76 | 63.37 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).